The precise genetic cause remains elusive in nearly 50% of patients with presumed neurogenetic disease, representing a significant barrier for clinical care. This is despite significant advances in clinical genetic diagnostics, including the application of whole-exome sequencing and next-generation sequencing-based gene panels. In this study, we identify a deep intronic mutation in the DMD gene in a patient with muscular dystrophy using both conventional and RNAseq-based transcriptome analyses. The implications of our data are that noncoding mutations likely comprise an important source of unresolved genetic disease and that RNAseq is a powerful platform for detecting such mutations.
Introduction
Neurogenetic diseases are a common cause of severe disability, associated with multiple morbidities, early mortality, and significant economic and societal costs. 1, 2 Muscular dystrophies (MDs) are prototypical neurogenetic disorders in that they are clinically and genetically heterogeneous but united by a common set of clinical and diagnostic observations (muscle weakness, elevated Creatine Phosphokinase (CPK), and dystrophic changes on muscle biopsy). 3 A critical existing issue in the MD field is that a significant number of children (~50%) with suspected disease do not yet have identified gene mutation(s) despite extensive genetic analysis. 4 This fact presents a major barrier to clinical care by prolonging the diagnostic odyssey for patients and families, by limiting care recommendations and prognostic information, and by exposing patients to potentially unnecessary testing. 5 It also hinders research into disease pathogenesis and therapy development.
Whole-exome sequencing (WES), along with next-generation sequencing-based gene panels, represent a significant technical advance that has greatly improved genetic diagnostics. 6 However, there remains a large group of patients whose genetic cause has not been uncovered despite thorough investigation with these modalities. 4, 7 One potential and underexplored source of mutation is sequence variation that alters RNA expression and/or processing. Such mutations may occur at exon/intron boundaries, and thus be captured by WES, or occur outside of the standard exome (such as in deep intronic and intergenic regions). To date, while 15% of mutations in the Human Gene Mutation Database are predicted to alter splicing and/or gene expression, nearly all of these are This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
described at splice-site junctions. Only a small number of cases exist where mutations in intronic or intergenic sequences have been identified as the cause of disease. [8] [9] [10] These aspects of the genome are seldom examined in the context of neurogenetic disease; furthermore, next-generation sequencing based on RNA transcript analysis (RNAseq) has yet to be studied in this context. Here, we present a case of a deep intronic mutation as the cause of Duchenne MD, and show that RNAseq is an effective modality for detecting this mutation.
Methods and Results
We encountered a 6-year-old boy with the insidious onset of gait abnormalities. He had been normally developing until age 2.5 years when he began experiencing increased trips and falls. After assessment by a family practitioner, a serum CPK study was sent, and was found to be elevated at >16,000 l/L (normal 55-300). His physical examination was notable for shoulder and calf muscle hypertrophy, limb-girdle muscle weakness, mild bilateral ankle contractures, a positive Gowers sign, and a waddling gait. On the basis of these features, we initiated clinical genetic testing for Duchenne MD, 11 including multiplex ligationdependent probe amplification-based deletion/duplication analysis of the DMD gene and direct Sanger sequencing of DMD coding sequence and intron/exon boundaries. These investigations did not reveal a causative mutation.
Because his clinical picture was consistent with the diagnosis of MD, we next sent a next-generation sequencing-based gene panel that examined all coding exons of the known limb-girdle MD genes (35 genes, Emory Genetics Laboratory). 4 No causative mutation was detected using this strategy. We then performed a diagnostic muscle biopsy, which revealed histologic changes consistent with a MD (Fig. 1A) . Immunostaining showed absent dystrophin expression in the majority of fibers ( Fig. 1B and C) , suggestive of a mutation at the DMD locus. We therefore used the remaining muscle biopsy material to analyze the DMD transcript, using both a standard approach and RNA-seq.
For conventional analysis, we performed overlapping RT-PCR reactions covering the entire DMD gene (Fig. 1D ). We detected altered cDNA products (size greater than predicted) with all primer sets that included both exons 37 and 38. We sequenced one of the altered products and uncovered a novel 51 base pair insertion between exons 37 and 38 corresponding to a discrete sequence fragment within intron 37 (Fig. 1E) . We next analyzed genomic DNA corresponding to the area surrounding the inserted sequence, and identified a single sequence variant in intron 37 (g.chrX:32,366,860 A>C [c. 5326-215 T>G] ). This variant creates a novel splice acceptor site, which then pairs with a cryptic splice donor site in the intron to create an aberrant 51 base pair exon (Fig. 1D ). This aberrant exon creates a frameshift and premature stop codon in the DMD coding sequence (Fig. 1F) , and is consistent with the absent protein expression seen by immunostaining. On the basis of this, we concluded that this sequence variant is causative for disease in our patient.
RNAseq analysis proved to be equally as informative. We isolated RNA from~15 mg of biopsy from our patient and from three controls (RNA integrity value (RIN) values ranging from 7.2 to 9.5). We generated libraries with an Illumina, San Diego, CA, USA. TruSeq V2 mRNA library kit and performed RNAseq on an Illumina HiSeq 2000 to average depth of 50-100 million paired end reads of transcript sequence per sample. 12 Reads were aligned to the hg19 reference assembly using RNA-STAR 13 and Gencode Release 19 transcriptome annotations.
14 To detect unannotated transcripts and isoforms, we performed unguided transcriptome assembly for each sample using Cufflinks 15 ; these were then annotated against the reference transcriptome. Unsupervised cluster analysis based on gene expression levels definitively distinguished the patient sample from controls ( Fig. 2A) . Examination of the patient's transcriptome identified altered transcript levels (>threefold) in 1197 genes relative to controls (FDR-adjusted P > 0.05), with DMD the third most significantly reduced transcript (Fig. 2B) . Examination of the DMD transcript showed relatively uniform reduction in all exons (Fig. 2C) , whereas dedicated interrogation of DMD transcript identified a single novel change corresponding to an insertion of transcribed sequence from intron 37 (Fig. 2C and D) . We then determined the specific location and length of this sequence, and it corresponded exactly to the altered fragment we identified by the conventional analysis. In all, RNA-seq rapidly and correctly identified the causative abnormality in the DMD transcript.
To test the potential utility of RNAseq as a clinical diagnostic technique, we then analyzed the data in a semiblinded fashion. RNAseq source files from our patient and controls were given random numbers and sent blinded (without clinical or genetic information) for analysis to the McArthur laboratory. We (the McArthur group) then independently and unambiguously identified the DMD transcript abnormality, including detection of the unique sequence variant in the intron that was found by genomic DNA sequencing to be the causative gene mutation (Fig. 3A and B) . As we were interested in RNAseq as a potential clinical diagnostic tool, we additionally documented comprehensive coverage of several major muscle specific transcripts, including DMD and other large, complex and likely low abundance transcripts (ex: LAMA2, RYR1 and NEB, Fig. 3C ). We also determined that at our read depth of 100 million reads we found in our patient sample~20 reads supporting the intron 37 inclusion DMD transcript (as opposed to zero in the controls or 150 samples from GTEx). These additional data thus confirm that RNA-seq can identify a disease associated transcript variant in a nonbiased fashion, and provide baseline measurements that suggest RNAseq can 
Discussion
This case study illustrates two important concepts. First, it adds to a small but growing group of cases where noncoding mutations lying outside the intron/exon boundary are identified as the cause of neurogenetic disease. [8] [9] [10] 16 This provides support to our prediction that a significant fraction of the currently "unsolved" cohort of patients with MD and other similar genetic diseases are due to mutations that alter RNA processing and/or expression.
Identification of such mutations will likely require analysis of nonexomic sequence sources, including RNA (as was done in this case) and genomic noncoding DNA. Second, our study demonstrates for the first time the potential utility of RNAseq for the identification of mutations that alter RNA transcript processing and/or expression. 17 Using RNAseq, we were able to quickly and accurately detect a noncoding mutation in DMD. Given that essentially all-known muscle disease genes are adequately captured and represented by RNAseq, the technology is likely applicable across the broad spectrum of muscle disease. This is particularly true given that muscle biopsy material is available for analysis in many cases. Also, it is possible to perform RNA analysis on myotubes derived from myoD-driven transdifferentiation of fibroblasts, 18 therefore obviating the requirement for muscle biopsy material for generating usable RNAseq data. This opens the broader possibility of application of RNAseq to a range of neurogenetic disorders, using for example, neurons derived in vitro either through direct reprogramming 19 or from induce Plupripotent stem (iPS) cells. 20 Lastly, of note, the specific mutation identified in our case is unusual as it occurs deep in an intron and it creates a novel exon with splice acceptor and donor independent from the surrounding exons. Importantly, investigation of this genomic variant by combined annotation-dependent depletion (CADD) analysis places it only in the 10th percentile in terms of pathogenicity, meaning that it would likely be ranked only in the top 300,000 of disease-relevant variants in our patient's genome. Based on this, it is possible that this mutation would not have been considered pathogenic in the absence of transcript data, and instead would have been coded as a VOUS or even a benign variant. Given the potentially high rate of VOUS in the noncoding genome, this raises the question as to whether whole-genome sequencing on its own will be adequate to uncover such mutations, or if RNA analysis will be a critical required element for establishing pathogenicity of noncoding mutations. With the speed and potential accuracy of RNAseq (as well as the price, which is equivalent to WES), it is possible that it may represent a linked or even preferred modality.
